{"schema_version":"secwatch.filing_event.v1","accession":"0001326110-24-000115","form_type":"8-K","ticker":"IBRX","cik":"0001326110","company_name":"ImmunityBio, Inc.","filed_at":"2024-11-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.114262+00:00","generated_at":"2026-05-29T22:24:27.070997+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"ImmunityBio reports 71% complete response rate in 100-patient ANKTIVA trial; durable responses up to 54 months","bullets":["100 patients with BCG-unresponsive NMIBC CIS enrolled; 71% achieved complete response (CR) rate.","Durable response duration ranged up to 54 months in responders, supporting cystectomy avoidance.","Updated data to be submitted to EMA in Marketing Authorization Application in Q4 2024.","CR rate consistent with 71% reported for 82 patients in NEJM Evidence (Chamie 2022).","Study continues to monitor durability of responses and overall survival outcomes."],"urls":{"canonical":"https://secwatch.observer/filing/0001326110-24-000115","json":"https://secwatch.observer/filing/0001326110-24-000115.json","markdown":"https://secwatch.observer/filing/0001326110-24-000115.md","text":"https://secwatch.observer/filing/0001326110-24-000115.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1326110/000132611024000115/0001326110-24-000115-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1326110/000132611024000115/ibrx-20241119.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T22:24:27.070997+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}